Ngl Fine-Chem Ltd. (BSE: 524774) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,736 Cr, it ranks #1,308 by market cap among the 6,137 Indian listed companies on FinBizNet, and #40 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,645.20 (as of 25 Oct 2026), the share price is 26.6% below its 52-week high of ₹3,602.00 and 108.1% above its 52-week low of ₹1,271.00. The share price is up 71.5% over one year and down 17.5% over three months.
| Current Price | ₹2,645.20 |
|---|---|
| Market Cap | ₹1,736 Cr |
| BSE Code | 524774 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 35.4 |
| Return on Equity | 15.74% |
| Return on Assets | 6.77% |
| 52-Week Range | ₹1,271.00 – ₹3,602.00 |
| 1-Year Price Change | +71.5% |
| 3-Month Price Change | -17.5% |
| Beta (1Y) | 0.43 |
| Dividend Yield | 0.06% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.nglfinechem.com |
| Revenue | ₹139 Cr |
|---|---|
| Net Profit | ₹18 Cr |
| Net Margin | 13.2% |
| EPS (Basic) | ₹29.78 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride t
1. Pharmaceuticals-This segment manufactures and exports veterinary and human active pharmaceutical ingredients, intermediates, and finished dosage forms.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Ngl Fine-Chem Ltd. | ₹1,736 Cr | 35.4 | 15.74% | ₹139 Cr | +71.5% |
Listed by market capitalisation. Ratios are shown for context only.
Ngl Fine-Chem Ltd. is trading at ₹2,645.20, with a market capitalisation of ₹1,736 Cr.
Ngl Fine-Chem Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ngl Fine-Chem Ltd. has a P/E of 35.4 and a return on equity of 15.74%.
Ngl Fine-Chem Ltd. is listed on the BSE under the scrip code 524774.
Ngl Fine-Chem Ltd.'s share price is up 71.5% over one year and down 17.5% over three months. Its 52-week range is ₹1,271.00 to ₹3,602.00.
In Q1 FY27, Ngl Fine-Chem Ltd. reported revenue of ₹139 Cr and net profit of ₹18 Cr, with basic EPS of ₹29.78 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.